New therapeutic approaches to the alphaherpesvirus infections

Journal of Antimicrobial Chemotherapy

Volumn 39, Issue 2, 1997, Pages 119-128

  Cassady, Kevin A ^a   Whitley, Richard J ^a  

^a CHILDREN S HOSPITAL OF ALABAMA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTIVIRUS AGENT; CIDOFOVIR; FAMCICLOVIR; IMIQUIMOD; MONOCLONAL ANTIBODY; PENCICLOVIR; PROTEINASE INHIBITOR; SORIVUDINE; VALACICLOVIR; VIRUS VACCINE;

ABDOMINAL PAIN; DIARRHEA; DRUG BIOAVAILABILITY; HEADACHE; HERPES SIMPLEX; HERPES VIRUS INFECTION; IMMUNE DEFICIENCY; NAUSEA; NEPHROTOXICITY; REVIEW; VIRUS ASSEMBLY; VIRUS CAPSID; VIRUS REPLICATION; VIRUS VIRULENCE; VOMITING;

2-AMINOPURINE; ACYCLOVIR; ALPHAHERPESVIRINAE; ANTIBODIES, MONOCLONAL; ARABINOFURANOSYLURACIL; CYTOSINE; HERPESVIRIDAE INFECTIONS; HUMANS; ORGANOPHOSPHORUS COMPOUNDS; PHOSPHONIC ACIDS; VALINE;

EID: 0031059174     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/39.2.119     Document Type: Review

References (77)

1. Levin, M. J. (1993). Impact of herpesvirus infections in the future. Journal of Medical Virology, Suppl. 1, 158-164.
2. Darby, G. (1993). The acyclovir legacy: its contribution to antiviral drug discovery. Journal of Medical Virology, Suppl, 1, 134-8.
3. Corey, L. & Spear, P. G. (1986). Infections with herpes simplex viruses (2). New England Journal of Medicine 314, 749-57.
4. Johnson, R. E., Nahmias, A. J., Magder, L. S., Lee, F. K., Brooks, C. A. & Snowden, C. B. (1989). A seroepidemiologic survey of the prevalence of herpes simplex virus type 2 infection in the United States. New England Journal of Medicine 321, 7-12.
5. Whitley, R. J. (1995). Herpes simplex viruses. In Fields Virology, Vol. 2, 3rd edn (Fields, B. N., Knipe, D. M. & Howley, P. M., Eds), pp. 2297-342. Raven Press, New York, NY.
6. Spring, S. B., Laughlin, C., Arvin, A. M., Hay, J., Straus, S. E., Whitley, R. J. et al. (1994). Workshop summary. Annals of Neurology 34, Suppl., S2-3.
7. Whitley, R. J. (1991). Perinatal herpes simplex virus infections. Reviews in Medical Virology 1, 101-10.
8. Whitley, R. J. (1990). Herpes simplex virus infections. In Infectious Diseases of the Fetus and Newborn Infant, 3rd edn (Remington, J. S. & Klein J. O., Eds), pp. 282-305. W. B. Saunders Company, Philadelphia, PA.
9. Balfour, H. H. (1993). Current management of varicella zoster virus infections. Journal of Medical Virology, Suppl. 1, 74-81.
10. Whitley, R. J. & Gnann, J. W. (1992). Acyclovir: a decade later. New England Journal of Medicine 327, 782-9.
11. Kimberlin, D. W., Coen, D. M., Biron, K. K., Cohen, J. I., Lamb, R. A., McKinlay, M. et al. (1995). Molecular mechanisms of antiviral resistance. Antiviral Research 26, 369-401.
12. Jacobson, M. A. (1993). Valaciclovir (BW256U87): the L-valyt ester of acyclovir. Journal of Medical Virology, Suppl. 1, 150-3.
13. Purifoy, D. J. M., Beauchamp, L. M., de Miranda, P., Ertl, P., Lacey, S., Roberts, G. et al. (1993). Review of research leading to new anti-herpesvirus agents in clinical development: valaciclovir hydrochloride (256U, the L-valyl ester of acyclovir) and 882C, a specific agent for varicella zoster virus. Journal of Medical Virology, Suppl. 1, 139-45.
14. Burnette, T. C. & de Miranda, P. (1994). Metabolic disposition of the acyclovir prodrug valaciclovir in the rat. Drug Metabolism and Disposition 22, 60-4.
15. Szczech, G. M. & de Miranda, P. (1995). Preclinical safety of valtrex (valaciclovir VACV) the L-valyl ester of acyclovir (ACV). Antiviral Research 26(3), A342.
16. Jacobson, M. A., Gallant, J., Wang, L. H., Coakley, D., Weller, S., Gary, D. et al. (1994). Phase I trial of valaciclovir, the L-valyl ester of acyclovir, in patients with advanced human immunodeficiency virus disease. Antimicrobial Agents and Chemotherapy 38, 1534-40.
17. Beutner, K. R., Friedman, D. J., Forszpaniak, C., Andersen, P. L. & Wood, M. J. (1995). Valaciclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults. Antimicrobial Agents and Chemotherapy 39, 1546-53.
18. Pue, M. A. & Benet, L. Z. (1993). Pharmacokinetics of famciclovir in man. Antiviral Chemistry and Chemotherapy 4, Suppl. 1, 47-55.
19. Vere Hodge, R. A. & Cheng, Y.-C. (1993). The mode of action of penciclovir. Antiviral Chemistry and Chemotherapy 4, Suppl. 1, 13-24.
20. Medical Economics Data Production Company. (1995). Famvir. In Physicians' Desk Reference, 49th edn, pp. 2374-6. Medical Economics Data Production Co., Montvale, NJ.
21. Saltzman, R., Jurewicz, R. & Boon, R. (1994). Safety of famciclovir in patients with herpes zoster and genital herpes. Antimicrobial Agents and Chemotherapy 38, 2454-7.
22. Gnann, J. W. (1994). New antivirals with activity against varicella-zoster virus. Annals of Neurology 35, Suppl., S69-72.
23. Safrin, S. (1995). Valtrex (valaciclovir VACV) for the treatment of recurrent genital herpes. Antiviral Research 26(3), A234.
24. Sacks, S. L., Bishop, A. M., Fox, R. & Lee, G. C. Y. (1994). A double-blind, placebo-controlled trial of the effect of chronically administered oral famciclovir on sperm production in men with recurrent herpes infection. Antiviral Research 23, Suppl. 1, 72.
25. Daniels, S. & Schentag, J. J. (1993). Drug interaction studies and safety of famciclovir in healthy volunteers: a review. Antiviral Chemistry and Chemotherapy 4, Suppl. 1, 57-64.
26. Scott, S. & Siederer, S. (1995). Pharmacokinetics of penciclovir following oral famciclovir in subjects with mild renal impairment. Antiviral Research 26(3), A340.
27. Dworkin, R. H., Boon, R. J. & Griffin, D. R. J. (1995). Famciclovir: effect on pain in herpes zoster. Antiviral Research 26(3), A344.
28. Tyring, S., Babarash, R. A., Nahlik, J. E., Cunningham, A., Marley, J., Heng, M. et al. (1995). Famciclovir for the treatment of acute herpes zoster. Effects on acute disease and postherpetic neuralgia: a randomized, double-blind, placebo-controlled trial. Collaborative Famciclovir Herpes Zoster Study Group. Annals of Internal Medicine 123, 89-96.
29. Sacks, S. L., Aoki, F. Y., Diaz-Mitoma, F., Sellors, J., Shafran, S., Romanowski, B. et al. (1994). Patient-initiated treatment of recurrent genital herpes with oral famciclovir: a Canadian, multicenter, placebo-controlled, dose-ranging study. In Abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, Orlando, FL, 1994. Abstract H 4, p. 11. American Society for Microbiology, Washington, DC.
30. Field, H. J. & Thackray, A. M. (1995). Famciclovir and valaci- clovir treatment during acute HSV-1 infection of mice have markedly different effects on subsequent virus reactivation from ganglia. Antiviral Research 26(3), A232.
31. Thackray, A. M. & Field, H. J. (1995). Comparative effects of famciclovir and valaciclovir on cutaneous and neurological HSV-1 infection in normal and immunocompromised mice. Antiviral Research 16(3), A328.
32. Machida, H. (1990). Brovavir: its antiherpesviral activity and mode of action. Advances in Experimental and Biology 278, 255-65.
33. Machida, H. (1986). Comparison of susceptibilities of varicellazoster virus and herpes simplex viruses to nucleoside analogs. Antimicrobial Agents and Chemotherapy 29, 524-6.
34. Machida, H., Endo, K., Watanabe, Y., Ashida, N. & Sakata, S. (1995). Inhibition of dihydropyrimidine dehydrogenase by 5-(E-2-bromo-vinyl) uracil (BV-Ura) and recovery of rat liver DPD activity after administration of BV-Ura or sorivudine. Antiviral Research 26(3), A341.
35. Wallace, M. R., Sawyer, M. H., Chamberlin, C. J., Hawkins, J. & Oldfield, E. C. (1994). BV-ara-U for the treatment of adult varicella. In Program and Abstracts of the Second International Conference on Varicella Zoster Virus Infections, 1994. Paris, France.
36. Whitley, R. J. (1996). Sorivudine: A potent inhibitor of varicella zoster virus replication. In Antiviral Chemotherapy 4: New Directions for Clinical Application and Research (Mills, J., Volberding, P. A. & Corey, L., Eds), pp. 41-4. Plenum Press, New York, NY.
37. DeHertogh, D., Boag, F., Bodworth, N., Burdge, D., Pacelli, L. & Multinational BV-araU Study Group. (1994). Sorivudine (BV-araU) versusacyclovir for herpes zoster in HIV-infected patients: Results of a multi-center controlled trial. In Program and Abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, Orlando, FL, 1994 (late breaker session). AmericanSociety for Microbiology, Washington, DC.
38. Burdge, D. R., Voigt, R., Gage, L., Lindley, J. I. & Sacks, S. (1995). Sorivudine (BV-ara-U) for the treatment of complicated refractory varicella zoster virus infection in HIV-infected patients. Antiviral Research 26(3), A343.
39. Yang, H. & Datema, R. (1991). Prolonged and potent therapeutic and prophylactic effects of (S)-1-[(3-hydroxy-2-phosphonylmethoxy)propyl] cytosine against herpes simplex virus type 2 infections in mice. Antimicrobial Agents and Chemotherapy 35, 1596-600.
40. Lalezari, J. P., Drew, W. L., Glutzer, E., Miner, D., Safrin, S., Owen, W. F. et al. (1994). Treatment with intravenous (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]-cytosine of acyclovir-resistant mucocutaneous infection with herpes simplex virus in a patient with AIDS. Journal of Infectious Diseases 170, 570-2.
41. Bronson, J. J., Ferrara, L. M., Hitchcock, M. J. M., Ho, H. T., Woods, K. L., Ghazzouli, I. et al. (1990). (S)-1-(3-hydroxy-2-(phosphonylmethoxy)propyl) cytosine (HPMPC): a potent antiherpesvirus agent. Advances in Experimental Medicine and Biology 278, 277-83.
42. Hitchcock, M. J. M., Lacy, S. A., Lindsey, J. R. & Kern, E. R. (1995). The cyclic congener of cidofovir has reduced nephrotoxicity in three species. Antiviral Research 26(3), A358.
43. Bischofberger, N., Hitchcock, M. J. M., Chen, M. S., Barkhimer, D. B., Cundy, K. C., Kent, K. M. et al. (1994). 1-[((S)-2- hydroxy-2-oxo-1,4,2-dioxaphosphorinan-5-yl)methyl] cytosine, an intracellular prodrug for (S)-1-(3-hydroxy-2-phosphonylmethoxy)- propyl) cytosine with improved therapeutic index in vivo. Antimicrobial Agents and Chemotherapy 38, 2387-91.
44. Lee, W. A., Shaw, J. -P., Bidgood, A., Eisenberg, E. & Cundy, K. C. (1995). Tissue distribution and unavailability of cyclic HPMPC, an intracellular prodrug of HPMPC. Antiviral Research 26(3), A340.
45. Gordon, Y. J., Romanowski, E. G. & Araullo-Cruz, T. (1994). HPMPC, a broad-spectrum topical antiviral agent, inhibits herpes simplex type 1 replication and promotes healing of dendritic keratitis in the New Zealand rabbit ocular model. Cornea 13, 516-20.
46. Bravo, F. J., Stanberry, L. R., Kier, A. B., Vogt, P. E. & Kern, E. R. (1993). Evaluation of HPMPC therapy for primary and recurrent genital herpes in mice and guinea pigs. Antiviral Research 21, 59-72.
47. Clement, J. J. & Kern, E. R. (1991). Cyclobutyl compounds as antiviral agents. Transplantation Proceedings 23, Suppl. 3, 159-61.
48. Petty, B. G., Wachsman, M., Jordan, M. C., Burgee, H., DeHertogh, D., Collins, D. et al. (1995). Sequential ascending multiple-dose safety and pharmacokinetic study of oral lobucavir (BMS-180194) in asymptomatic volunteers seropositive for HIV and CMV. Antiviral Research 26 (3), A296.
49. O'Brien, W. J., Coe, E. C. & Taylor, J. L. (1990). Nucleoside metabolism in herpes simplex virus-infected cells following treatment with interferon and acyclovir, a possible mechanism of synergistic antiviral activity. Antimicrobial Agents and Chemotherapy 34, 1178-82.
50. Villani, G., Pillaire, M.-J. & Boehmer, P. E. (1994). Effect of the major DNA adduct of the antitumor drug cis-diamminedichloroplatinum (II) on the activity of a helicase essential for DNA replication, the herpes simplex virus type-1 origin-binding protein. Journal of Biological Chemistry 269, 21676-81.
51. Matthews, J. T., Terry, B. J. & Field, A. K. (1993). Structure and function of the HSV DNA replication proteins: defining novel antiviral targets. Antiviral Research 20, 89-114.
52. Martinez, R., Shao, L. & Weller, S. K. (1992). The conserved helicase motifs of the herpes simplex virus type 1 origin-binding protein UL9 are important for function. Journal of Virology 66, 6735-46.
53. Zhu, L. A. & Weller, S. K. (1992). The six conserved helicase motifs of the UL5 gene product, a component of the herpes simplex virus type 1 helicase-primase, are essential for its function. Journal of Virology 66, 469-79.
54. Lawrence, G. L., Nicholas, J. & Barrell, B. G. (1995). Human herpesvirus 6 (strain U1102) encodes homologues of the conserved herpesvirus glycoprotein gM and the alphaherpesvirus origin-binding protein. Journal of General Virology 76, 147-52.
55. Liu, F. Y. & Roizman, B. (1991). The herpes simplex virus 1 gene encoding a protease also contains within its coding domain the gene encoding the more abundant substrate. Journal of Virology 65, 5149-56.
56. Dilanni, C. L., Stevens, J. T., Bolgar, M., O'Boyle, D. R., Weinheimer, S. P. & Colonno, R. J. (1994). Identification of the serine residue at the active site of the herpes simplex virus type 1 protease. Journal of Biological Chemistry 269, 12672-6.
57. Preston, V. G., Coates, J. A. V. & Rixon, F. J. (1983). Identification and characterization of a herpes simplex virus gene product required for encapsidation of virus DNA. Journal of Virology 45, 1056-64.
58. Safrin, S., Schacker, T., Delehanty, J., Hill, E. & Corey, L. (1993). Potential for combined therapy with 348U87, a ribonucleotide reductase inhibitor, and acyclovir as treatment for acyclovirresistant herpes simplex virus infection. Journal of Medical Virology, Suppl. 1, 146-9.
59. Paradis, H., Langelier, Y., Michaud, J., Brazeau, P. & Gaudreau, P. (1991). Studies on in vitro proteolytic sensitivity of peptides inhibiting herpes simplex virus ribonucleotide reductases lead to discovery of a stable and potent inhibitor. International Journal of Peptide and Protein Research 37, 72-9.
60. Marsh, M. & Helenius, A. (1989). Virus entry into animal cells. Advances in Virus Research 36, 107-51.
61. Srinivas, R. V., Birkedal, B., Owens, R. J., Anantharamaiah, G. M., Segrest, J. P. & Compans, R. W. (1990). Antiviral effects of apolipoprotein A-1 and its synthetic amphipathic peptic analogs. Virology 176, 48-57.
62. Aboudy, Y., Mendelson, E., Shalit, I., Bessalle, R. & Fridkin, M. (1994). Activity of two synthetic amphiphilic peptides and magainin-2 against herpes simplex virus types 1 and 2. International Journal of Peptide and Protein Research 43, 573-82.
63. Reising, S. F., Quinn, K. W. & Stanberry, L. R. (1995). In vitro activity of bile acids on herpes simplex type-2 (HSV-2) infection. Antiviral Research 26(3), A308.
64. Shupack, J., Stiller, M., Knobler, E., Ackerman, C., Jondreau, L. & Kenny, C. (1990). Topical alpha-interferon in recurrent genital herpes simplex infection. A double-blind, placebo-controlled clinical trial. Dermatologica 181, 134-8.
65. Berkowitz, C. & Becker, Y. (1992). Recombinant interleukin-1α, interleukin-2 and M-CSF-1 enhance the survival of newborn C57BL/6 mice inoculated intraperitoneally with a lethal dose of herpes simplex virus-1. Archives of Virology 124, 83-93.
66. Imbertson, L. M., Beaurline, J. M., Gerster, J. F., Gibson, S. J., Horton, V. L., Miller, R. L. et al. (1995). Antiviral and immunomodulating activities of the imidazoquinolone S-28463. Antiviral Research 26(3), A301.
67. Harrison, C. J., Miller, R. L. & Bernstein, D. I. (1995). Adjuvant effect of imiquimod when combined with HSV glycoprotein vaccine in guinea pigs with recurrent HSV-2 genital herpes. Antiviral Research 26(3), A233.
68. Whitley, R. J. (1994). Neonatal herpes simplex virus infections: is there a role for immunoglobulin in disease prevention and therapy? Pediatric Infectious Disease Journal 13, 432-9.
69. Straus, S. E., Corey, L., Burke, R. L., Savarese, B., Barnum, G., Krause, P. R. et al. (1994). Placebo-controlled trial of vaccination with recombinant glycoprotein D of herpes simplex virus type 2 for immunotherapy of genital herpes. Lancet 343, 1460-3.
70. Helenius, A., Doxsey, S. & Mellman, I. (1987). Viruses as tools in drug delivery. Annals of the New York Academy of Sciences 507, 1-6.
71. Chou, J., Kern, E. R., Whitley, R. J. & Roizman, B. (1990). Mapping of herpes simplex virus-1 neurovirulence to gamma 134.5, a gene nonessential for growth in culture. Science 250, 1262-6.
72. Chambers, R., Gillespie, G. Y., Soroceanu, L., Andreansky, S., Chatterjee, S., Chou, J. et al. (1995). Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a scid mouse model of human malignant glioma. Proceedings of the National Academy of Sciences of the United States of America 92, 1411-5.
73. Gershon, A. A. (1991). Human immune responses to live attenuated varicella vaccine. Reviews of Infectious Diseases 13, Suppl. 11, 3957-9.
74. Arvin, A. M. (1992). Cell-mediated immunity to varicella-zoster virus. Journal of Infectious Diseases 166, Suppl. 1, S35-41.
75. Gershon, A. A., LaRussa, P., Hardy, I., Steinberg, S. & Silverstein, S. (1992). Varicella vaccine: the American experience. Journal of Infectious Diseases 166, Suppl. 1, S63-8.
76. American Academy of Pediatrics - Committee on Infectious Diseases. (1995). Recommendations for the use of live attenuated varicella vaccine. Pediatrics 95, 791-6.
77. Nader, S., Bergen, R., Sharp, M. & Arvin, A. M. (1995). Age-related differences in cell-mediated immunity to varicella-zoster virus among children and adults immunized with live attenuated varicella vaccine. Journal of Infectious Diseases 171, 13-7.